iPS在临床应用的新进展  

Progress in the clinical application of iPS

作　　者：常清[1] 洪明[1] 

机构地区：[1]重庆市第九人民医院普外一科,重庆北碚400700

出　　处：《现代生物医学进展》2009年第21期4169-4171,共3页Progress in Modern Biomedicine

摘　　要：诱导性多潜能干细胞,即iPS细胞,是近年来干细胞领域最令人瞩目的一项新的干细胞制造技术,这个技术通过特定的基因组合与转染可以将已分化的体细胞诱导重编程为未分化的多能细胞。与胚胎干细胞(ES)不同,iPS细胞的制造不需要胚胎组织,也不涉及伦理学问题,更重要的是制备iPS细胞可以采用病人自己的体细胞制备,避免免疫排斥反应,并且来源广泛,因此给再生医学实践于临床带来了新的曙光。目前,iPS的研究尚处于初级阶段,本文就iPS的研究现状与已有在临床应用相关的实验报道作以综述。Induced pluripotent stem cells,iPS cell in short,is the most motivating stem cells manufacture technique in the field of steam cells. This technique induces and reprograms the differentiated somatic cells into undifferentiated pluripotent cells by using specific genetic combination and transfection. Different from the embryonicstemcells（ES） ,the manufacture of iPS cells does not need the embryonal tissue,Ethical Considerations,and have vast resources as well,so it brings a new path for regeneration medicine used in clinical practice. At present,the research of iPS is still in its infancy,this paper will summarize the current research situation and the existed clinical application reports of iPS.

关 键 词：诱导性多潜能干细胞 IPS细胞 体细胞重编 

分 类 号：Q75[生物学—分子生物学] Q813